Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Initial review, 60149 [2015-25274]
Download as PDF
<![CDATA[
60149
Federal Register / Vol. 80, No. 192 / Monday, October 5, 2015 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Form name
Safety and Health Managers ..........................
Occupational Safety and Health Program
Survey.
Informed Consent Form .................................
Non Responder Interview ..............................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–25194 Filed 10–2–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on DSK4VPTVN1PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: Initial review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) PS16–001, Minority HIV/AIDS
Research Initiative (MARI) to Build HIV
Prevention Treatment and Research
Capacity in Disproportionately Affected
Black and Hispanic Communities and
Among Historically Underrepresented
Researchers.
DATES: 10:00 a.m.–5:00 p.m., December
9–10, 2015 (Closed).
ADDRESSES: Teleconference.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, National
Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention (NCHHSTP),
CDC, 1600 Clifton Road NE., Mailstop
E60, Atlanta, Georgia 30333, Telephone:
(404) 718–8833.
SUPPLEMENTARY INFORMATION:
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
VerDate Sep<11>2014
18:34 Oct 02, 2015
Jkt 238001
applications received in response to
‘‘Minority HIV/AIDS Research Initiative
(MARI) to Build HIV Prevention
Treatment and Research Capacity in
Disproportionately Affected Black and
Hispanic Communities and Among
Historically Underrepresented
Researchers’’, FOA PS16–001.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2015–25274 Filed 10–2–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2015–0016]
Final Revised Vaccine Information
Materials for Seasonal Influenza
Vaccines
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
Under the National
Childhood Vaccine Injury Act (NCVIA)
(42 U.S.C. 300aa–26), the HHS/CDC
must develop vaccine information
materials that all health care providers
are required to give to patients/parents
prior to administration of specific
vaccines. On May 20, 2015, CDC
published a notice in the Federal
Register (80 FR 29009) seeking public
comments on proposed new vaccine
information materials for inactivated
and live attenuated influenza vaccines.
Following review of comments
submitted and consultation as required
SUMMARY:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(in hours)
4,404
1
20/60
4,404
792
1
1
2/60
5/60
under the law, CDC has finalized the
materials. Copies of the final vaccine
information materials for inactivated
and live attenuated influenza vaccines
are available to download from https://
www.cdc.gov/vaccines/hcp/vis/
index.html or https://
www.regulations.gov (see Docket
Number CDC–2015–0016).
DATES: Beginning no later than March 1,
2016, each health care provider who
administers any seasonal influenza
vaccine to any child or adult in the
United States shall provide copies of the
relevant revised vaccine information
materials contained in this notice, in
conformance with the August 7, 2015
CDC Instructions for the Use of Vaccine
Information Statements prior to
providing such vaccinations. These
revised vaccine information materials
may also be used earlier than that date.
Prior to March 1, 2016, the previous
edition of these two VISs can be used.
FOR FURTHER INFORMATION CONTACT:
Suzanne Johnson-DeLeon (msj1@
cdc.gov), National Center for
Immunization and Respiratory Diseases,
Centers for Disease Control and
Prevention, Mailstop A–19, 1600 Clifton
Road, NE., Atlanta, Georgia 30329.
SUPPLEMENTARY INFORMATION: The
National Childhood Vaccine Injury Act
of 1986 (Pub. L. 99–660), as amended by
section 708 of Public Law 103–183,
added section 2126 to the Public Health
Service Act. Section 2126, codified at 42
U.S.C. 300aa–26, requires the Secretary
of Health and Human Services to
develop and disseminate vaccine
information materials for distribution by
all health care providers in the United
States to any patient (or to the parent or
legal representative in the case of a
child) receiving vaccines covered under
the National Vaccine Injury
Compensation Program (VICP).
Development and revision of the
vaccine information materials, also
known as Vaccine Information
Statements (VIS), have been delegated
by the Secretary to the Centers for
Disease Control and Prevention (CDC).
Section 2126 requires that the materials
be developed, or revised, after notice to
the public, with a 60-day comment
E:\FR\FM\05OCN1.SGM
05OCN1
]]>Agencies
[Federal Register Volume 80, Number 192 (Monday, October 5, 2015)]
[Notices]
[Page 60149]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-25274]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel: Initial review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to Funding Opportunity Announcement (FOA)
PS16-001, Minority HIV/AIDS Research Initiative (MARI) to Build HIV
Prevention Treatment and Research Capacity in Disproportionately
Affected Black and Hispanic Communities and Among Historically
Underrepresented Researchers.
DATES: 10:00 a.m.-5:00 p.m., December 9-10, 2015 (Closed).
ADDRESSES: Teleconference.
FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention (NCHHSTP), CDC, 1600 Clifton Road
NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.
SUPPLEMENTARY INFORMATION:
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Minority HIV/AIDS Research Initiative (MARI) to Build HIV
Prevention Treatment and Research Capacity in Disproportionately
Affected Black and Hispanic Communities and Among Historically
Underrepresented Researchers'', FOA PS16-001.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2015-25274 Filed 10-2-15; 8:45 am]
BILLING CODE 4163-18-P
